News

Dermatology Advisor2d
Zoryve Foam 0.3% Approved for Plaque Psoriasis of the Scalp, Body
The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.
Rheumatology Advisor2d
Biologics for Psoriasis Effect Hematological and Lipid Parameters
Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.
Clinical Trials Arena on MSN2d
Alumis concludes enrolment in Phase III programme of plaque psoriasis therapy
The programme comprises two Phase III trials, ONWARD1 and ONWARD2, and an optional long-term extension trial, ONWARD3.
Everyday Health2d
Invisible Inflammation Is a Stealthy Psoriasis Threat
About 1 in 3 people with psoriasis who achieved clear skin with biologic drugs still had underlying inflammation that may ...
The American Journal of Managed Care2d
Biosimilar Starjemza Gains FDA Approval as Ustekinumab Shows Significant Psoriasis-Itch Relief
Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...
Healio3d
Intervention improves timely postoperative treatment for people with head and neck cancer
Healio: How problematic are treatment delays in head and neck cancer? Graboyes: Unlike some cancers — breast, lung, colon or prostate, for example — there is no screening test for head and ...